DOCSLIB.ORG

Boards' Fodder #2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

boards’ fodder #2 Inborn Errors of Metabolism by Kristina Burke, MD, and Erin Adams, MD DISORDER DEFECT SKIN FINDINGS OTHER Alkaptonuria Homogentistic acid oxidase Blue-grey pigmentation of nose, - Large joint arthropathy (Endogenous ochronosis) ears, axillae, genitalia and - Intervertebral disc calcification AR Disorder of phenylalanine cartilage. Blue sclera (Osler’s - Mitral/aortic valve disease and tyrosine metabolism. sign), dark urine (pH >7), black - Nephrolithiasis Homogentistic acid accumu- cerumen lates Fabry’s disease α-galactosidase A Angiokeratomas (esp lower - Renal failure, cardiovascular events, (Angiokeratoma Corporis (glycolipids accumulate in skin, extremities, scrotum, penis, and strokes Diffusum) heart, kidneys) lower trunk), whorl-like corneal - Acroparesthesias and painful crises XLR opacities, edema, hypohIdrosis - Maltese cross in urine A lysosomal storage disease - Enzyme replacement available Fucosidosis α-L- fucosidase Angiokeratomas, coarse fea- - Mental retardation (MR), neurologic AR tures, facial dysmorphism deterioration A lysosomal storage disease Gaucher disease Acid-β-glucosidase (glucocer- Type 1: diffuse hyperpigmenta- ALL: hepatosplenomegaly (HSM) AR ebrosidase) tion, petechiae, pingueculae of - Type I: Adult type, Ashkenazi Jews, no A lysosomal storage disease Leads to accumulation of glu- sclera CNS involvement cocerebroside in histiocytes - Type 2: infantile, rapid neuro (Gaucher’s cells) Type 2: congenital ichthyosis, deterioration, aspiration pneumonia collodian baby - Type 3: juvenile chronic neuropathic Phenylketonuria Phenylalanine hydroxylase Pigmentary dilution of skin, hair, - MR, seizures AR (Phenylalanine not oxidized to eyes (fair complexion, blond hair, - Phenylpyruvic acid in urine (musty odor) tyrosine) blue eyes), pseudoscleroderma, - Screened for at birth eczematous dermatitis - Dietary restriction Tyrosinemia II Tyrosine aminotransferase Painful palmoplantar kerato- - Herpetiform keratitis, blindness Kristina Burke, MD, is (Richner-Hanhart) (hepatic) derma - MR a third year resident at AR TAT gene - Corneal ulcers Walter Reed National Military Medical Center Homocystinuria Cystathionine β-synthase Fair complexion, malar flush, - Thromboembolic events (50% by 30yo) AR livedo reticularis, leg ulcers = common cause of death in Bethesda, Md. Sparse, fine hair - Ectopia lentis (downward) Marfinoid habitus - Osteoporosis - MR, developmental delay Niemann-Pick disease Type A and B: Type A and B: ochre to brownish- Type A: severe, CNS deterioration, AR Sphingomyelinase (SMPD1) yellow discoloration of skin, HSM, failure to thrive Type C: NPC1 and 2 papular lesions face and upper Type B: spares CNS, survival to A lysosomal storage disease extremities, xanthomas adulthood Type C: childhood, HSM, developmental delay, psychomotor deterioration Trimethylaminuria Mutation of flavin-containing Skin, urine, and sweat smell like - Smell due to accumulation of “Fish odor syndrome” monooxygenase type 3 (FMO3) “rotting fish” trimethylamine gene - Avoid choline in diet Erin Adams, MD, is a Lesch-Nyhan HPRT1 gene leading to hypo- Loss of tissue around mouth and - MR, choreoathoid movements, staff dermatologist at (juvenile gout) xanthine-guanine fingers (due to self-mutilation) self-mutilation Walter Reed National XLR phosphoribosyl transferase Tophaceous deposits - Orange crystals in diaper Military Medical (HGPRT) deficiency (hyperuricemia) Center and also academic staff Wilson’s disease Defect in ATP7B gene Blue lunulae, Kayser-Fleischer - HSM, cardiomyopathy, renal tubular for the National (Hepatolenticular (hepatic copper transporting rings (copper deposition in acidosis Capital Consortium degeneration) ATPase) Descemet’s membrane), green- - Progressive neurologic dysfunction Dermatology AR ish discoloration of face, neck (dysrthria, ataxia, dementia) and genitalia, pretibial hyperpig- - Lab: low ceruloplasmin Residency Program. mentation - Tx: penicillamine, trientine, zinc supple- ment Hartnup disease SLC6A19 gene Pellegra-like dermatitis (photo- - Cerebellar ataxia, MR AR (neutral amino acid transporter) sensitive eruption on face, arms, - Tends to improve with age neck, legs) - Defect in tryptophan transport irinections D Residency p. 4 • Fall 2012 boards’ fodder #2 Inborn Errors of Metabolism (continued) by Dr. Burke, MD and Dr. Adams, MD DISORDER DEFECT SKIN FINDINGS OTHER Do you have an Prolidase deficiency Deficiency of the enzyme Skin fragility, lower - Mental deficiency, recurrent infections, interesting Boards’ prolidase extremity ulceration, syndromic facies telangiectasias, poliosis Fodder? We’re expanding our Citrullinemia Type 1: argininosuccinic acid Resembles zinc deficiency - Clears with arginine supplementation synthetase (ASS1 gene) Erythematous, erosive, scaling Boards’ Fodder Type 2: SLC25A13 gene patches periorally, lower archives and you abdomen, and diaper area can be a part of it. Contact Dean Farber disease Ceramidase deficiency Periarticular swelling, rubbery - Onset first month of life, death by age 2 Monti, managing A lysosomal storage disease SQ nodules - Weak, hoarse cry; pulmonary failure, MR editor, special publications, at Adrenoleukodystrophy ALD gene Hyperpigmentation, mild - Progressive demyelination of cerebral (Schilder’s disease) ichthyosis, sparse hair with white matter [email protected]. X-linked trichorrhexis nodosa-like features CADASIL NOTCH 3 gene Findings on skin biopsy - Depression, migraine headaches Cerebral autosomal dominant (eosinophilic granular material - Multiple cerebral infarcts leading to arteriopathy w/ subcortical in arterial walls) early dementia If you enjoyed this infarcts and leukoencepha- - Most common hereditary stroke special Boards’ lopathy disorder Fodder edition, let us know. Write to Lafora disease EPM2A- encoding laforin Few – rarely see papulonodular - Progressive epilepsy syndrome [email protected]. (Lafora progressive myoclonic EMP2B – encodes a ubiquitin lesions over ears, plaques on - Dementia and ataxia epilepsy) ligase arms - Best site to biopsy = axilla (Lafora bodies around eccrine ducts) Alagille syndrome JAG 1 -Xanthomas, jaundice - Congenital intrahepatic biliary Need more Boards’ AD -Unusual facies hypoplasia w/ cholestasis and pruritus. Fodder? Visit - Hyperlipidemia - Butterfly-shaped vertebra the Directions in Residency archive Sitosterolemia ABCG5 (encoding sterolin-1) or Tuberous and tendinous - Elevated plasma levels of plant sterols AR ABCG8 (encoding sterolin-2) xanthomas during the first - Arthritis, premature vascular disease, listed under “phytosterolemia” decade of life high risk of fatal cardiac events during “Publications” at teenage years www.aad.org. Hurler syndrome Deficiency of α-L-iduronidase Diffuse fine lanugo hair, extensive - MR, HSM, corneal opacities, umbilical AR blue pigmentation hernia “gargoylism” Facial dysmorphism, large - Dental abnormalities, persistent rhinitis A lysosomal storage disease tongue, thick lips Hunter syndrome Deficiency of iduronate-2-sul- Skin-colored pebbly lesions of - Dysotosis multiplex XLR fatase the upper back, neck, chest, A lysosomal storage disease proximal extremities Tangier Disease ATP-binding cassette (ABCA1) Tonsils are yellow and enlarged. - HSM, lymph node enlargement, periph- AR transport protein: almost com- Maculopapular eruption over eral neuropathy, corneal (Familial α-lipoprotein defi- plete absence of plasma HDL trunk and abdomen infiltration in adults ciency) and massive deposition of cho- - Premature coronary artery disease lesterol esters in tissues References: 1. Bolognia JL, Jorizzo JL, Rapini RP, editors. Bolognia Textbook of Dermatology. 2 nd ed. Spain: Mosby Elsevier publishing; 2008: chapters 48 and 62. 2. James WD, Berger TG, Elston DM, eds. Andrews’ Diseases of the Skin: Clinical Dermatology. 11th ed. Philadelphia, Pa: Saunders Elsevier; 2011: chap 26. 3. Spitz JL. Genodermatoses: A clinical guide to genetic skin disorders. Philadelphia: Lippincott Williams & Wilkins; 2005: chapters 8 and 11. irinections Fall 2012 • p. 5 D Residency.
Recommended publications
  • Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment

    Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment

    Pediatr Nephrol DOI 10.1007/s00467-011-1838-5 EDUCATIONAL REVIEW Hyperammonemia in review: pathophysiology, diagnosis, and treatment Ari Auron & Patrick D. Brophy Received: 23 September 2010 /Revised: 9 January 2011 /Accepted: 12 January 2011 # IPNA 2011 Abstract Ammonia is an important source of nitrogen and is the breakdown and catabolism of dietary and bodily proteins, required for amino acid synthesis. It is also necessary for respectively. In healthy individuals, amino acids that are not normal acid-base balance. When present in high concentra- needed for protein synthesis are metabolized in various tions, ammonia is toxic. Endogenous ammonia intoxication chemical pathways, with the rest of the nitrogen waste being can occur when there is impaired capacity of the body to converted to urea. Ammonia is important for normal animal excrete nitrogenous waste, as seen with congenital enzymatic acid-base balance. During exercise, ammonia is produced in deficiencies. A variety of environmental causes and medica- skeletal muscle from deamination of adenosine monophos- tions may also lead to ammonia toxicity. Hyperammonemia phate and amino acid catabolism. In the brain, the latter refers to a clinical condition associated with elevated processes plus the activity of glutamate dehydrogenase ammonia levels manifested by a variety of symptoms and mediate ammonia production. After formation of ammonium signs, including significant central nervous system (CNS) from glutamine, α-ketoglutarate, a byproduct, may be abnormalities. Appropriate and timely management requires a degraded to produce two molecules of bicarbonate, which solid understanding of the fundamental pathophysiology, are then available to buffer acids produced by dietary sources. differential diagnosis, and treatment approaches available.
  • Melanocytes and Their Diseases

    Melanocytes and Their Diseases

    Downloaded from http://perspectivesinmedicine.cshlp.org/ on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Melanocytes and Their Diseases Yuji Yamaguchi1 and Vincent J. Hearing2 1Medical, AbbVie GK, Mita, Tokyo 108-6302, Japan 2Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 Correspondence: [email protected] Human melanocytes are distributed not only in the epidermis and in hair follicles but also in mucosa, cochlea (ear), iris (eye), and mesencephalon (brain) among other tissues. Melano- cytes, which are derived from the neural crest, are unique in that they produce eu-/pheo- melanin pigments in unique membrane-bound organelles termed melanosomes, which can be divided into four stages depending on their degree of maturation. Pigmentation production is determined by three distinct elements: enzymes involved in melanin synthesis, proteins required for melanosome structure, and proteins required for their trafficking and distribution. Many genes are involved in regulating pigmentation at various levels, and mutations in many of them cause pigmentary disorders, which can be classified into three types: hyperpigmen- tation (including melasma), hypopigmentation (including oculocutaneous albinism [OCA]), and mixed hyper-/hypopigmentation (including dyschromatosis symmetrica hereditaria). We briefly review vitiligo as a representative of an acquired hypopigmentation disorder. igments that determine human skin colors somes can be divided into four stages depend- Pinclude melanin, hemoglobin (red), hemo- ing on their degree of maturation. Early mela- siderin (brown), carotene (yellow), and bilin nosomes, especially stage I melanosomes, are (yellow). Among those, melanins play key roles similar to lysosomes whereas late melanosomes in determining human skin (and hair) pigmen- contain a structured matrix and highly dense tation.
  • University of Cincinnati

    University of Cincinnati

    UNIVERSITY OF CINCINNATI Date: August 29, 2006 I, Smita Chawla hereby submit this work as a part of the requirements of the degree of: Doctor of Philosophy (Ph. D.) in: Pharmaceutical Sciences It is entitled: Effect of deoxyArbutin and it’s second-generation derivatives on melanocyte viability and function. on Human Nail Permeabili ty . This work and its defense approved by: R. Randall Wickett, Ph.D., Chair Raymond E. Boissy, Ph.D. William Cacini, Ph.D. Prashiela Manga, Ph.D. Marty O. Visscher, Ph.D. EFFECT OF DEOXYARBUTIN AND ITS SECOND-GENERATION DERIVATIVES ON MELANOCYTE VIABILITY AND FUNCTION A dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in the Division of Pharmaceutical Sciences of the College of Pharmacy 2006 by Smita Chawla B.S. in Pharmaceutical Sciences Mumbai University, Mumbai, India, 2001 Committee Chair: Randall Wickett, Ph.D. ABSTRACT Therapeutic treatment of skin pigmentary disorders such as melasma, solar lentigines, and post inflammatory hyperpigmentation has been challenging and seldom completely successful. The majority of these therapies target tyrosinase, a key enzyme required for pigment synthesis. The lack of success is due to the less than desired efficacy and safety of tyrosinase inhibitors marketed as skin lightening agents (i.e. hydroquinone, kojic acid and arbutin). We propose that the tyrosinase inhibitor deoxyArbutin (dA) and second-generation derivatives of dA, deoxyFuran, thio-dA, and fluoro-dA, have the potential to be effective inhibitors of skin melanization. In this study, we have analyzed the modulating effects of dA and its derivatives on melanocyte function and viability.
  • Incidence of Inborn Errors of Metabolism by Expanded Newborn

    Incidence of Inborn Errors of Metabolism by Expanded Newborn

    Original Article Journal of Inborn Errors of Metabolism & Screening 2016, Volume 4: 1–8 Incidence of Inborn Errors of Metabolism ª The Author(s) 2016 DOI: 10.1177/2326409816669027 by Expanded Newborn Screening iem.sagepub.com in a Mexican Hospital Consuelo Cantu´-Reyna, MD1,2, Luis Manuel Zepeda, MD1,2, Rene´ Montemayor, MD3, Santiago Benavides, MD3, Hector´ Javier Gonza´lez, MD3, Mercedes Va´zquez-Cantu´,BS1,4, and Hector´ Cruz-Camino, BS1,5 Abstract Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results.
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies

    EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies

    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
  • Inherited Metabolic Disease

    Inherited Metabolic Disease

    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
  • Amino Acid Disorders 105

    Amino Acid Disorders 105

    AMINO ACID DISORDERS 105 Massaro, A. S. (1995). Trypanosomiasis. In Guide to Clinical tions in biological fluids relatively easy. These Neurology (J. P. Mohrand and J. C. Gautier, Eds.), pp. 663– analyzers separate amino acids either by ion-ex- 667. Churchill Livingstone, New York. Nussenzweig, V., Sonntag, R., Biancalana, A., et al. (1953). Ac¸a˜o change chromatography or by high-pressure liquid de corantes tri-fenil-metaˆnicos sobre o Trypanosoma cruzi in chromatography. The results are plotted as a graph vitro: Emprego da violeta de genciana na profilaxia da (Fig. 1). The concentration of each amino acid can transmissa˜o da mole´stia de chagas por transfusa˜o de sangue. then be calculated from the size of the corresponding O Hospital (Rio de Janeiro) 44, 731–744. peak on the graph. Pagano, M. A., Segura, M. J., DiLorenzo, G. A., et al. (1999). Cerebral tumor-like American trypanosomiasis in Most amino acid disorders can be diagnosed by acquired immunodeficiency syndrome. Ann. Neurol. 45, measuring the concentrations of amino acids in 403–406. blood plasma; however, some disorders of amino Rassi, A., Trancesi, J., and Tranchesi, B. (1982). Doenc¸ade acid transport are more easily recognized through the Chagas. In Doenc¸as Infecciosas e Parasita´rias (R. Veroesi, Ed.), analysis of urine amino acids. Therefore, screening 7th ed., pp. 674–712. Guanabara Koogan, Sa˜o Paulo, Brazil. Spina-Franc¸a, A., and Mattosinho-Franc¸a, L. C. (1988). for amino acid disorders is best done using both South American trypanosomiasis (Chagas’ disease). In blood and urine specimens. Occasionally, analysis of Handbook of Clinical Neurology (P.
  • Summary Current Practices Report

    Summary Current Practices Report

    18/10/2011 EU Tender “Evaluation of population newborn screening practices for rare disorders in Member States of the European Union” Short Executive Summary of the Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA Countries Authors: Peter Burgard1, Martina Cornel2, Francesco Di Filippo4, Gisela Haege1, Georg F. Hoffmann1, Martin Lindner1, J. Gerard Loeber3, Tessel Rigter2, Kathrin Rupp1, 4 Domenica Taruscio4,Luciano Vittozzi , Stephanie Weinreich2 1 Department of Pediatrics , University Hospital - Heidelberg (DE) 2 VU University Medical Centre - Amsterdam (NL) 3 RIVM - Bilthoven (NL) 4 National Centre for Rare Diseases - Rome (IT) The opinions expressed in this document are those of the Contractor only and do not represent the official position of the Executive Agency for Health and Consumers. This work is funded by the European Union with a grant of Euro 399755 (Contract number 2009 62 06 of the Executive Agency for Health and Consumers) 1 18/10/2011 Abbreviations 3hmg 3-Hydroxy-3-methylglutaric aciduria 3mcc 3-Methylcrotonyl-CoA carboxylase deficiency/3-Methylglutacon aciduria/2-methyl-3-OH- butyric aciduria AAD Disorders of amino acid metabolism arg Argininemia asa Argininosuccinic aciduria bio Biotinidase deficiency bkt Beta-ketothiolase deficiency btha S, beta 0-thalassemia cah Congenital adrenal hyperplasia cf Cystic fibrosis ch Primary congenital hypothyroidism citI Citrullinemia type I citII Citrullinemia type II cpt I Carnitin
  • Inborn Errors of Metabolism

    Inborn Errors of Metabolism

    Inborn Errors of Metabolism Mary Swift, Registered Dietician (R.D.) -------------------------------------------------------------------------------- Definition Inborn Errors of Metabolism are defects in the mechanisms of the body which break down specific parts of food into chemicals the body is able to use. Resulting in the buildup of toxins in the body. Introduction Inborn Errors of Metabolism (IEM) are present at birth and persist throughout life. They result from a failure in the chemical changes that are metabolism. They often occur in members of the same family. Parents of affected individuals are often related. The genes that cause IEM are autosomal recessive. Thousands of molecules in each cell of the body are capable of reactions with other molecules in the cell. Special proteins called enzymes speed up these reactions. Each enzyme speeds up the rate of a specific type of reaction. A single gene made up of DNA controls the production of each enzyme. Specific arrangements of the DNA correspond to specific amino acids. This genetic code determines the order in which amino acids are put together to form proteins in the body. A change in the arrangement of DNA within the gene can result in a protein or enzyme that is not able to carry out its function. The result is a change in the ability of the cell to complete a particular reaction resulting in a metabolic block. The areas of the cell these errors occur determine the severity of the consequences of the break down in metabolism. For example if the error occurs in critical areas of energy production, the cell will die.
  • Alkaptonuria.Pdf

    Alkaptonuria.Pdf

    Alkaptonuria Description Alkaptonuria is an inherited condition that causes urine to turn black when exposed to air. Ochronosis, a buildup of dark pigment in connective tissues such as cartilage and skin, is also characteristic of the disorder. This blue-black pigmentation usually appears after age 30. People with alkaptonuria typically develop arthritis, particularly in the spine and large joints, beginning in early adulthood. Other features of this condition can include heart problems, kidney stones, and prostate stones. Frequency This condition is rare, affecting 1 in 250,000 to 1 million people worldwide. Alkaptonuria is more common in certain areas of Slovakia (where it has an incidence of about 1 in 19, 000 people) and in the Dominican Republic. Causes Mutations in the HGD gene cause alkaptonuria. The HGD gene provides instructions for making an enzyme called homogentisate oxidase. This enzyme helps break down the amino acids phenylalanine and tyrosine, which are important building blocks of proteins. Mutations in the HGD gene impair the enzyme's role in this process. As a result, a substance called homogentisic acid, which is produced as phenylalanine and tyrosine are broken down, accumulates in the body. Excess homogentisic acid and related compounds are deposited in connective tissues, which causes cartilage and skin to darken. Over time, a buildup of this substance in the joints leads to arthritis. Homogentisic acid is also excreted in urine, making the urine turn dark when exposed to air. Learn more about the gene associated with Alkaptonuria • HGD Inheritance This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations.
  • Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia

    Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia

    003 1-399819113005-0435$03.00/0 PEDIATRIC RESEARCH Vol. 30, No. 5, 1991 Copyright 0 199 1 International Pediatric Research Foundation, Inc. Pr~ntc.d in U.S. A Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia ALBERT0 PONZONE, ORNELLA GUARDAMAGNA, SILVIO FERRARIS, GIOVANNI B. FERRERO, IRMA DIANZANI, AND RICHARD G. H. COTTON InstiflifeofPediatric Clinic(A.P., O.G., S.F., G.B.F., I.D.], University of Torino, 10126 Torino, Italy and Olive Miller Laboratory [R.G.H.C.],Murdoch Institute, Royal Children's Hospital, Vicroria,Australia 3052 ABSTRACT. Some cases of primary hyperphenylalanine- PKU to describe some cases clinically unresponsive to a Phe- mia are not caused by the lack of phenylalanine hydroxyl- restricted diet and later shown to be due to BH4 deficiency ase, but by the lack of its cofactor tetrahydrobiopterin. ( 1-4). These patients are not clinically responsive to a phenylal- By analyzing all the essential components of the complex anine-restricted diet, but need specific substitution therapy. hydroxylation system of aromatic amino acids, it became appar- Thus, it became necessary to examine all newborns ent that a defect in the BH4 recycling enzyme DHPR (EC screened as positive with the Guthrie test for tetrahydro- 1.66.99.7) and two defects in BH4 synthetic pathway enzymes, biopterin deficiency. Methods based on urinary pterin or guanosine triphosphate cyclohydrolase I (EC 3.5.4.16) and 6- on specific enzyme activity measurements are limited in PPH4S, may lead to cofactor deficiency resulting in HPA and in their availability, and the simplest method, based on the impaired production of dopamine and serotonin (5-7).
  • Amino Acid Disorders

    Amino Acid Disorders

    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.